Milton Werner
Fondatore presso INHIBIKASE THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 30/04/2024
Posizioni attive di Milton Werner
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/09/2008 | - |
| Amministratore Delegato | 01/09/2008 | - | |
| Fondatore | 01/09/2008 | - | |
| Presidente | 01/09/2008 | - | |
| Contatto Relazioni con gli Investitori | 01/09/2008 | - | |
| Winship Cancer Institute | Corporate Officer/Principal | - | - |
Storia della carriera di Milton Werner
Precedenti posizioni note di Milton Werner
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Direttore Tecnico/Scientifico/R&S | 01/05/2007 | 01/08/2007 |
| The Rockefeller University | Corporate Officer/Principal | 01/09/1996 | 01/06/2007 |
Formazione di Milton Werner
| University of California, Berkeley | Doctorate Degree |
| University of Southern California | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
| Winship Cancer Institute |
- Borsa valori
- Insiders
- Milton Werner
- Esperienza
